Abstract
The case of a 65 year old man with ischemic cardiomyopathy, an ICD device and recurrent electrical storms is presented. The patient had been implanted with an ICD device due to aborted sudden death. The first electrical storm occured 12 months later. It was terminated by the administration of intravenous amiodarone and the patient was discharged on maintenance dose amiodarone and b-blocker. After a period of 3 months during which the patient remained asymptomatic, a second arrhythmic clustering occured and it was controlled by the addition of mexiletine. A total number of 429 appropriate shocks had been delivered by the device. Thereafter and for a seven month follow-up period, the patient remains asymptomatic under this combination of antiarrhythmic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kowey PR, Levine JH, Herre JM, et al. Randomized, double blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995; 92: 3255–3263.
Credner SC, Klingenheben T, Mauss O, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators. Incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32: 1909–1915.
Zipes DP, Roberts D. For the pacemaker-cardioverterdefibrillator investigators. Results of the international study of the implantable pacemaker cardioverterdefibrillator: a comparison of epicardial and endocardial lead systems. Circulation 1995; 92: 59–65.
Scheinman MM, Levine JH, Cannom DS, et al. Doseranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995; 92:3264–3272.
Hohnloser SH, Klingenheben T, Singh BN, et al. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade des pointes tachycardia. Ann Int Med 1994; 121: 529–535.
Jung W, Manz M, Pizzulli L, et al. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992; 70: 1023–1027.
Daoud EG, Ching Man K, Horwood L, et al. Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements. Am J Cardiol 1997; 79: 97–100.
Gottlieb SS, McCarter RJ, Vogel RA, et al. Effect of beta-blockade on mortality among high-risk and lowrisk patients after myocardial infarction.NEngl J Med 1998; 339: 489–497.
Toivonen L, Kadish A, Morady F, et al. A prospective comparison of class Ia, b and c antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. Circulation 1991; 84: 101–108.
Waleffe A, Rabine May L, Kulbertus HE, et al. Combined mexiletine and amiodarone treatment of refractory recurrent ventricular tachycardia. Am Heart J 1980; 100: 788–793.
Aizawa Y, Abe A, Ohira K, et al. Preferential action of mexiletine on central common pathway of reentrant ventricular tachycardia. J Am Coll Cardiol 1996; 28: 1759–1764.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manolis, A.G., Katsivas, A.G., Vassilopoulos, C. et al. Case Report: Electrical Storms in an ICD-Recipient with 429 Delivered Appropriate Shocks: Therapeutic Management with Antiarrhythmic Drug Combination. J Interv Card Electrophysiol 6, 91–94 (2002). https://doi.org/10.1023/A:1014188526158
Issue Date:
DOI: https://doi.org/10.1023/A:1014188526158